港股，全线反攻！

Group 1 - The core viewpoint of the article highlights the recent rebound in the Hong Kong stock market, with the Hang Seng Index rising by 0.75%, the Hang Seng Tech Index increasing by 1.12%, and the Hong Kong Stock Connect Internet Index up by 0.88% [1][16] - The improvement in external liquidity expectations is a significant factor, as U.S. inflation has unexpectedly slowed, strengthening market expectations for the Federal Reserve to lower interest rates next year, which is beneficial for offshore markets like Hong Kong [1][16] - Domestic capital has played a crucial role, with net inflows from southbound funds exceeding 1.4 trillion HKD this year, demonstrating the long-term commitment of mainland investors to Hong Kong assets [1][16] Group 2 - Market sentiment and valuation recovery are evident, as major indices in Hong Kong are now at historically low valuation levels, providing a significant margin of safety [1][16] - The policy environment remains accommodative, with recent economic meetings confirming that a moderately loose monetary policy will continue next year to promote stable economic growth, providing a macro-level confidence foundation for the market [1][16] - The latest report from CITIC Securities indicates that after a unilateral rise in September, the Hong Kong market has experienced fluctuations since October due to overseas macro expectations, with quality assets now entering a high cost-performance ratio zone [1][16] Group 3 - The article discusses various Hong Kong ETFs, including the Hong Kong Internet ETF, which tracks the CSI Hong Kong Internet Index and focuses on leading internet companies through the Stock Connect, benefiting from the core dividends of China's digital economy [3][18] - The Hong Kong Innovation Drug ETF, which tracks the Hang Seng Hong Kong Stock Connect Innovation Drug Select Index, has seen its shares reach a new high of 4.178 billion, reflecting long-term value recognition despite recent adjustments [7][20] - The Hong Kong Medical ETF is highlighted for its low valuation and high growth expectations, with a TTM price-to-earnings ratio of 30.44, which is significantly lower compared to A-shares and U.S. medical sectors, indicating a pricing advantage [12][25]